Evan Leitner

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.

Cooley advised the underwriters in ADC Therapeutics’ $60 million follow-on offering. Jefferies acted as sole book-running manager for the offering. ADC Therapeutics is a commercial-stage, oncology-focused biotechnology company involved in the development of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. Partners Richard Segal and Div Gupta led the Cooley team.

Cooley advised the underwriters in Aura Biosciences’ $86.7 million follow-on offering. SVB Securities, Cowen and Evercore ISI acted as joint bookrunning managers for the offering. Aura is a clinical-stage biotechnology company that is leveraging its novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Partners Rich Segal, Div Gupta and Daniel Goldberg led the Cooley team.

Cooley advised the underwriters in Zentalis Pharmaceuticals’ $200 million follow-on offering of 10,330,000 shares of common stock at an offering price of $19.38 per share. Zentalis is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting fundamental biological pathways of cancers. Partners Richard Segal and Div Gupta led the Cooley team.